

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS PO. Box 1450 Alexandria, Vignina 22313-1450 www.nspto.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. FIRST NAMED INVENTOR APPLICATION NO. FILING DATE 9800 Phillip Dan Cook ISIS-4803 10/09/2001 09/973,981 05/29/2003 7590 32650 WOODCOCK WASHBURN LLP **EXAMINER** ONE LIBERTY PLACE - 46TH FLOOR RILEY, JEZIA PHILADELPHIA, PA 19103 ART UNIT PAPER NUMBER 1637 DATE MAILED: 05/29/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Summary		
	09/973,981	COOK ET AL.
	Examiner	Art Unit
The MAIL INC DATE of this communication and	Jezia Riley	1637
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status		
1) Responsive to communication(s) filed on 14 April 2003.		
2a) This action is FINAL . 2b) This action is non-final.		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is		
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims		
4) Claim(s) 1-6,8-20,32,33,35,40,42-44,63-68,72,79-81 and 88-109 is/are pending in the application.		
4a) Of the above claim(s) <u>1-6,13-20,43,44,91,92 and 94-100</u> is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>8-12,32,33,35,40,42,63-68,72,79-81,88-90,93 and 101-109</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) See Continuation Sheet are subject to restriction and/or election requirement.		
Application Papers 9)☐ The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.		
If approved, corrected drawings are required in reply to this Office action.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).		
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.		
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	7 5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)

Application/Control Number: 09/973,981

Art Unit: 1637

DETAILED ACTION

1. Applicant's election with traverse of group II in Paper No. 7, filed on 4/14/03, is acknowledged. The traversal is on the ground(s) that no adequate reasons and/or examples have been provided to support a conclusion of patentable distinctness between the inventions of groups I-V. This is not found persuasive because the inventions of group I., II-V are directed to different species. Additionally the invention of group II for example can be enzymatically synthesized. Further the invention of Group II can be used for the invention of group II or III, or IV or V, or it can be used as an antimetabolite for the treatment of certain carcinomas. Further the groups I-V represent separate invention, as shown by the USPTO classification system, as being in different classes and/or subclasses. Therefore if all the groups I-V were searched together it will impose a serious burden on the examiner. The requirement is still deemed proper and is therefore made FINAL.

Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

 The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 3. Claims 8-12, 32, 33, 35, 40, 42, 63-68, 72, 79-81, 88-90, 93, 101-109 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 09/973,981

Art Unit: 1637

4. Claims 101-109 are vague and indefinite because it is unclear what it is meant by "group that enhances the pharmacodynamic properties of oligonucleotides or a group that enhances the pharmacokinetic properties of oligonucleotides". The specification fails to provide an adequate written description of what constitutes a "group that enhances the pharmacodynamic properties of oligonucleotides or a group that enhances the pharmacokinetic properties of oligonucleotides". The specification provides no examples of structures capable of performing such functions. Further, it does not appear that one could determine whether or not a particular structure would be capable of performing such functions based on structural considerations alone. Therefore, the skilled artisan would be unable to envisage the invention as broadly claimed.

Double Patenting

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 09/973,981

Art Unit: 1637

- 6. Claims 101-103, 107-108 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 6335434. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are claiming identical compounds.
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jezia Riley whose telephone number is 703-305-6855. The examiner can normally be reached on 9:30AM 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on 703-308-1119. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

/ JEZIA RILEY PRIMARY EXAMINER

May 21, 2003

Continuation of Disposition of Claims: Claims subject to restriction and/or election requirement are 1-6,8-20,32,33,35,40,42-44,63-68,72,79-81 and 88-109.